Adoptive cellular immunotherapy combined with chemotherapy versus chemotherapy alone in Chinese patients with metastatic colorectal cancer: a cost-effectiveness analysis to inform drug pricing.

ABSTRACT:

Objective

To evaluate the cost-effectiveness of adoptive cellular immunotherapy (ACI) combined with chemotherapy versus chemotherapy alone in Chinese patients with metastatic colorectal cancer (mCRC) and provide evidence-based support for drug pricing strategies.

Methods

A Markov model was constructed using data from the NCT03950154 phase III clinical trial, which randomized 202 patients into two groups: ACI combined with oxaliplatin/capecitabine/bevacizumab (n=100) and chemotherapy alone (n=102). Clinical outcomes, including progression-free survival (PFS), overall survival (OS), and adverse events, were analyzed. Costs, quality-adjusted life-year (QALY), and incremental cost-effectiveness ratio (ICER) were calculated from the perspective of the Chinese healthcare system. P

SUBMITTER: Huo L 

PROVIDER: S-EPMC12150851 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature